Open Access Repository

TAK1 signaling is a potential therapeutic target for pathological angiogenesis


Downloads per month over past year

Zhu, L, Lama, S, Tu, L, Dusting, GJ, Wang, J-H and Liu, G ORCID: 0000-0003-3379-724X 2021 , 'TAK1 signaling is a potential therapeutic target for pathological angiogenesis' , Angiogenesis , doi: 10.1007/s10456-021-09787-5.

[img] PDF (Post-print)
TAK1 review_R1 ...pdf | Document not available for request/download
Full text restricted until 10 May 2022.


Angiogenesis plays a critical role in both physiological responses and disease pathogenesis. Excessive angiogenesis canpromote neoplastic diseases and retinopathies, while inadequate angiogenesis can lead to aberrant perfusion and impairedwound healing. Transforming growth factor β activated kinase 1 (TAK1), a member of the mitogen-activated protein kinasekinase kinase family, is a key modulator involved in a range of cellular functions including the immune responses, cell survival and death. TAK1 is activated in response to various stimuli such as proinfammatory cytokines, hypoxia, and oxidativestress. Emerging evidence has recently suggested that TAK1 is intimately involved in angiogenesis and mediates pathogenicprocesses related to angiogenesis. Several detailed mechanisms by which TAK1 regulates pathological angiogenesis havebeen clarifed, and potential therapeutics targeting TAK1 have emerged. In this review, we summarize recent studies of TAK1in angiogenesis and discuss the crosstalk between TAK1 and signaling pathways involved in pathological angiogenesis.We also discuss the approaches for selectively targeting TAK1 and highlight the rationales of therapeutic strategies basedonTAK1 inhibition for the treatment of pathological angiogenesis.

Item Type: Article
Authors/Creators:Zhu, L and Lama, S and Tu, L and Dusting, GJ and Wang, J-H and Liu, G
Keywords: transforming growth factor β activated kinase 1, angiogenesis, infammation, hypoxia, oxidative stress
Journal or Publication Title: Angiogenesis
Publisher: Springer Netherlands
ISSN: 0969-6970
DOI / ID Number: 10.1007/s10456-021-09787-5
Copyright Information:

© The Author(s), under exclusive licence to Springer Nature B.V. 2021. Post-prints are subject to Springer Nature re-use terms

Related URLs:
Item Statistics: View statistics for this item

Actions (login required)

Item Control Page Item Control Page